^
    Back
    Association details:
    Biomarker:EGFR T790M
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor) +
    pelcitoclax (APG-1252) (Bcl2 inhibitor, Bcl-xL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2021
    Title:

    MA02.06-Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC

    Published date:
    08/18/2021
    Excerpt:
    Of 20 efficacy-evaluable patients, a total of 3 partial responses were observed, including 2 patients with osimertinib-resistant NSCLC who had an EGFR T790M mutation….Combination treatment with pelcitoclax and osimertinib at RP2D was safe and feasible. Preliminary synergy and efficacy of both pelcitoclax and osimertinib were also observed in some patients with osimertinib-resistant NSCLC.
    Trial ID:
    NCT04001777